Astrazeneca, Sanofi-Gsk, Jansenn, Here are the companies that will sell the anti-Covid vaccines to the EU states
The European Commission has signed a contract with Janssen for the purchase by the EU of 200 million doses of the anti Covid vaccine. The agreement follows those signed with Astrazeneca and Sanofi-Gsk. All the details
While the infections from Covid 19 return to rise in the main European countries, Brussels paves the way to obtain Coronavirus vaccines in a short time (at least hopefully).
In the past few hours, the European Commission has signed a third contract with a pharmaceutical company, Janssen, controlled by the American group Johnson & Johnson. The signing follows those with Astrazeneca and Sanofi-GSK. Let's go step by step.
THE CONTRACT WITH JANSSEN
Let's start with the latest news. The European Commission has approved a third contract, this time with Janssen Pharmaceutica NV , daughter of Johnson & Johnson's pharmaceutical company Janssen.
The contract allows Member States to purchase 200 million doses of vaccines (with an option for another 200 million doses), through the Commission, which states that "Member States may also decide to donate the vaccine to middle-income countries and low or to redirect it to other European countries ”.
JANSSEN'S VACCINE
Janssen's Phase III clinical trial vaccine candidate leverages the AdVac® technology platform, which is also used to develop and manufacture Janssen's recently approved Ebola vaccine and Zika, RSV and HIV vaccine candidates.
THE WORDS OF VON DER LEYEN
"As the coronavirus continues to spread worryingly across Europe, it is essential to find a vaccine and quickly," commented European Commission President Ursula von der Leyen. “I am delighted that we were able to reach an agreement with Johnson & Johnson to purchase vaccines for 200 million people. This is our third contract with a pharmaceutical company. Our aim is to provide EU citizens with safe and effective vaccines as soon as they are found ”.
THE CONTRACT WITH ASTRAZENECA
The signing of the contract with Janssen follows that between the Commission and Astrazeneca . Under the agreement, all member states will be able to purchase 300 million doses of the AstraZeneca vaccine, with an option for an additional 100 million doses, to be distributed on a population-proportional basis.
The vaccine manufactured by Astrazeneca and developed by the University of Oxford, in collaboration with Irbm, is in phase two and three large-scale clinical trials.
THE CONTRACT WITH SANOFI-GSK
The formal signature of the contract between Sanofi-GSK and the Commission was also held in recent days. The agreement will allow all EU Member States to purchase up to 300 million doses of the vaccine currently in Phase I and Phase II trials (Phase 3 is expected to start by the end of the year). The vaccine
NEGOTIATIONS IN PROGRESS WITH CUREVAC, BIONTECH AND MODERN
The Commission intends to sign other and new contracts: in fact, exploratory talks are underway with CureVac, BioNTech-Pfizer (under examination at Ema ) and Moderna.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/astrazeneca-sanofi-gsk-jansenn-ecco-le-aziende-che-venderanno-agli-stati-ue-i-vaccini-anti-covid/ on Fri, 09 Oct 2020 05:30:16 +0000.